Selective Serotonin Reuptake Inhibitors: all 1,366 studies that test it

Page 12 of 14. Open to participants first (105), then studies with results posted, then the rest; newest registration first within each.

• Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major DepressionCompletedNCT00517764Not applicable
• A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual DysphoriaCompletedNCT00516113Phase 4
• Study of Fluoxetine in AutismCompletedNCT00515320Phase 3
• Subcutaneous Olanzapine for Hyperactive or Mixed DeliriumCompletedNCT00512291Not applicable
• Maintenance Study for Adolescent DepressionCompletedNCT00508859Phase 4
• Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled ReleaseStatus unknownNCT00492414Phase 4
• Repetitive Behavior Disorders in People With Severe Mental RetardationStatus unknownNCT00491478Phase 3
• Duloxetine Versus Paroxetine for Major DepressionCompletedNCT00489775Phase 3
• Olanzapine in Patients With Advanced Cancer and Weight LossCompletedNCT00489593Phase 1
• Escitalopram and Depression in Elderly Alzheimer's PatientsTerminatedNCT00488670Phase 3
• Weight Gain Management in Patients With SchizophreniaCompletedNCT00486005Phase 4
• Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With SchizophreniaCompletedNCT00485901Phase 3
• Flushing in Social Anxiety Disorder on CipralexCompletedNCT00485888Phase 2
• Assessment of a Weight Management Program for Weight Gain in Patients With SchizophreniaCompletedNCT00485823Phase 4
• Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With SchizophreniaCompletedNCT00485810Phase 1/2
• Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I DepressionCompletedNCT00485771Phase 4
• Olanzapine Versus Comparator in the Treatment of Bipolar DisorderCompletedNCT00485680Phase 3
• Managing Acute Schizophrenia, a Comparison Between Two Atypical AntipsychoticsCompletedNCT00485498Phase 4
• Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance TreatmentTerminatedNCT00464191Phase 4
• A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic AttacksCompletedNCT00457106Not applicable
• Escitalopram in Schizophrenia in OCD- Open Label StudyCompletedNCT00456937Phase 4
• Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 PathwayCompletedNCT00456898Phase 1
• Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant ResponseCompletedNCT00456430Phase 4
• Escitalopram and Sleep Architecture in Patients With Major Depressive DisorderStatus unknownNCT00442481Phase 4
• Zyprexa and Task Engagement in SchizophreniaWithdrawnNCT00440843Phase 3
• Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological GamblingCompletedNCT00438776Phase 3
• Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSDCompletedNCT00433121Phase 4
• Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive DisorderCompletedNCT00432614Phase 3
• Prozac Treatment of Major Depression: Discontinuation StudyCompletedNCT00427128Phase 4
• Galantamine Augmentation of Escitalopram for Treatment of DepressionTerminatedNCT00423969Phase 4
• Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.CompletedNCT00421369Not applicable
• Escitalopram in Depressive Patients With Acute Coronary Artery SyndromeCompletedNCT00419471Phase 4
• Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)CompletedNCT00418171Phase 4
• Study for Evaluating Different Methods of Measuring Depression Treatment ResponseCompletedNCT00406952Not applicable
• A Combination Therapy In Patients With Social Anxiety DisorderCompletedNCT00403962Phase 2
• Treatment Of Patients With Social Anxiety DisorderCompletedNCT00397722Phase 2
• Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 PolymorphismCompletedNCT00397059Phase 4
• Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.CompletedNCT00394056Phase 2
• Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major DepressionCompletedNCT00386841Phase 4
• Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed PatientsCompletedNCT00384436Phase 4
• Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.CompletedNCT00380224Phase 3
• Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal DementiaCompletedNCT00376051Phase 4
• Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant MedicationCompletedNCT00375843Phase 4
• Preventing Depression Recurrence in DiabetesCompletedNCT00374426Phase 4
• Efficacy Study of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism.CompletedNCT00368862Phase 4
• Citalopram in Treating Postmenopausal Women With Hot FlashesCompletedNCT00363909Phase 3
• Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of ParoxetineCompletedNCT00357045Phase 4
• Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and AdolescentsCompletedNCT00353028Phase 4
• Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and AdolescentsTerminatedNCT00352768Phase 4
• Switch Study of Existing Atypical Antipsychotics to BifeprunoxCompletedNCT00347425Phase 3
• PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety PatientsCompletedNCT00343707Phase 2
• Effect of Brain Lesion Severity on Treatment Response in Late-Life DepressionCompletedNCT00339066Not applicable
• Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral TherapyCompletedNCT00338767Phase 2
• Determining Optimal Continuation Treatment Duration for Depressed Children and AdolescentsCompletedNCT00332787Not applicable
• Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or ParkinsonismCompletedNCT00331825Phase 4
• Exercise Training Versus Drug Therapy for Treating Depression in Older AdultsCompletedNCT00331305Phase 3
• Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance DependenceCompletedNCT00330239Phase 4
• Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy SubjectsCompletedNCT00329147Phase 3
• Short-Term Versus Long-Term Treatment for Severe Premenstrual Syndrome (PMS)CompletedNCT00318773Phase 4
• Social Anxiety Disorder Study Of ParoxetineCompletedNCT00318669Phase 3
• Trial of Citalopram for the Prevention of DepressionCompletedNCT00317746Phase 3
• Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)CompletedNCT00305500Phase 3
• SWitching to Abilify Trial (SWAT)CompletedNCT00304616Phase 4
• PTSD Prevention Using EscitalopramCompletedNCT00300313Not applicable
• Augmentation Study of Levetiracetam in Obsessive Compulsive DisorderTerminatedNCT00299611Phase 2/3
• Serotonin, Impulsivity, and Cocaine Dependence TreatmentCompletedNCT00297505Phase 2
• Memory Functioning and Antidepressant TreatmentCompletedNCT00296933Phase 3
• Treatment of Depression Following Multiple Brain TestsCompletedNCT00296777Phase 4
• Are Two Antidepressants a Good Initial Treatment for Depression?CompletedNCT00296712Phase 4
• Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic PainCompletedNCT00291148Phase 3
• Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive DisorderCompletedNCT00290914Phase 2
• Appetite Increase in Schizophrenia Patients Treated With Atypical AntipsychoticsCompletedNCT00290121Phase 4
• Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid MetabolismCompletedNCT00287820Phase 4
• Study of Amantadine for Weight Stabilization During Olanzapine TreatmentCompletedNCT00287352Phase 1
• Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With ResponseCompletedNCT00285376Phase 3
• Flushes and Sertraline TrialCompletedNCT00283192Not applicable
• Lexapro in the Treatment of Patients With Postpartum DepressionCompletedNCT00277108Not applicable
• Bipolar II Depression: Lithium, SSRI, or the CombinationCompletedNCT00276965Phase 3
• Sertraline for the Prevention of Recurrent Postpartum DepressionCompletedNCT00276900Phase 3
• A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)CompletedNCT00275197Phase 2
• Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled TrialWithdrawnNCT00273624Phase 3
• A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety DisorderCompletedNCT00273039Phase 2
• Treatment Resistant Bipolar DepressionTerminatedNCT00272025Phase 1
• Study Evaluating SCA-136 in Subjects With Acute Exacerbations of SchizophreniaCompletedNCT00265551Phase 2
• Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research GroupCompletedNCT00265291Phase 2
• Long-term Study Of Paroxetine in Women and MenCompletedNCT00264654Phase 3
• Modulation of Visually Evoked Potentials by an AntidepressantCompletedNCT00263133Not applicable
• Treatment of Orthostatic IntoleranceActive, not recruitingNCT00262470Phase 1/2
• Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF ReturneesCompletedNCT00261729Not applicable
• Escitalopram Treatment of Patients With Agitated DementiaCompletedNCT00260624Phase 4
• Combination Of PAXIL Tablet And BenzodiazepinesCompletedNCT00259883Phase 4
• SB-773812 Administered In Adults With SchizophreniaCompletedNCT00259870Phase 2
• DBT and Escitalopram in Borderline Personality DisorderStatus unknownNCT00255554Not applicable
• The Role of Cytokine-Serotonin Interactions in Post-Stroke DepressionCompletedNCT00254020Phase 4
• Depression and Traumatic Brain InjuryCompletedNCT00254007Phase 4
• Discontinuation Study Of Citalopram (Antidepressant) in Depressed AdolescentsWithdrawnNCT00249886Phase 3
• Study of PET Scans and Serotonin in Hot Flashes TreatmentTerminatedNCT00249847Not applicable
• Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1TerminatedNCT00249431Phase 2
• Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)CompletedNCT00249405Phase 2
• Side Effects of Newer Antipsychotics in Older AdultsCompletedNCT00245206Phase 4

← Selective Serotonin Reuptake Inhibitors overview